Educational Resources

Prescription Guides

Evidence-based guides to help you understand prescriptions, compare options, and navigate the healthcare system.

How to Get TRT Prescribed Online

Featured Guide

How to Get TRT Prescribed Online

Ready for testosterone therapy? This step-by-step guide explains how to qualify for online TRT, what happens during the visit, and what treatment costs.

⏱ 8 min read · Read guide →

Weight Loss & GLP-1s

9 guides
Teens Left Behind? New Data on GLP-1 Prescribing Disparities in Youth Obesity

Teens Left Behind? New Data on GLP-1 Prescribing Disparities in Youth Obesity

A 2026 JAMA Pediatrics analysis shows teens of color and low-income backgrounds receive GLP-1 prescriptions far less often than peers despite similar obesity ra…

⏱ 6 min read · Aug 10, 2026 Read →
Roche’s CT-388 Dual Agonist Hits 22% Weight Loss—How It Compares

Roche’s CT-388 Dual Agonist Hits 22% Weight Loss—How It Compares

CT-388 reached placebo-adjusted weight loss of 22.5 % in Phase II. Explore key numbers, safety, and how it measures up to existing incretin therapies.…

⏱ 7 min read · Aug 10, 2026 Read →
Oral Aleniglipron Delivers 11% Weight Loss in Phase 2b

Oral Aleniglipron Delivers 11% Weight Loss in Phase 2b

Bristol Myers Squibb’s small-molecule GLP-1 agonist aleniglipron produced double-digit weight loss in the 36-week Phase 2b ACCESS trial.…

⏱ 5 min read · Aug 9, 2026 Read →
Ecnoglutide vs Semaglutide: 20-Week Phase 2 Weight Loss

Ecnoglutide vs Semaglutide: 20-Week Phase 2 Weight Loss

A new head-to-head study suggests ecnoglutide may outperform semaglutide for weight loss. We break down the 20-week data and what it means for future treatment.…

⏱ 8 min read · Aug 9, 2026 Read →
Tirzepatide Lowers Cardio-Renal Risk 20%: July 2026 SURPASS

Tirzepatide Lowers Cardio-Renal Risk 20%: July 2026 SURPASS

Fresh July 2026 data from SURPASS-CVOT reveal that tirzepatide delivers a meaningful cardiorenal benefit over dulaglutide. See what the numbers mean for patient…

⏱ 7 min read · Aug 9, 2026 Read →
DA-1726 Early Results: Dual-Action Peptide for Obesity & MASH

DA-1726 Early Results: Dual-Action Peptide for Obesity & MASH

Early human data reveal that once-weekly DA-1726 produces rapid weight and waist reductions with a mild side-effect profile, positioning the peptide as a promis…

⏱ 8 min read · Aug 9, 2026 Read →
Setmelanotide for Hypothalamic Obesity: What the New FDA Label Means for Care

Setmelanotide for Hypothalamic Obesity: What the New FDA Label Means for Care

The FDA now allows setmelanotide to treat acquired hypothalamic obesity. Discover who qualifies, how the drug is dosed, expected weight-loss results, and key sa…

⏱ 8 min read · Aug 9, 2026 Read →
CagriSema vs Semaglutide vs Tirzepatide: New Weight-Loss Data

CagriSema vs Semaglutide vs Tirzepatide: New Weight-Loss Data

New 2026 data reveal how the CagriSema combo stacks up against semaglutide and tirzepatide for weight loss. Explore results, safety, and next steps.…

⏱ 8 min read · Aug 9, 2026 Read →
Semaglutide for Alcohol Use Disorder: Insights from 2026 Lancet RCT

Semaglutide for Alcohol Use Disorder: Insights from 2026 Lancet RCT

The first large randomized trial finds once-weekly semaglutide reduces heavy drinking days in people with alcohol use disorder and obesity. Here’s what the data…

⏱ 7 min read · Aug 9, 2026 Read →
View Care Options →

OmenRx does not prescribe medications.